Vaccines for COVID-19: Where do we stand in 2021?

被引:61
|
作者
Sharma, Ketaki [1 ,2 ]
Koirala, Archana [1 ,2 ,3 ]
Nicolopoulos, Katrina [1 ]
Chiu, Clayton [1 ,2 ]
Wood, Nicholas [1 ,2 ]
Britton, Philip N. [2 ,4 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Nepean Hosp, Dept Infect Dis, Penrith, NSW, Australia
[4] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW, Australia
关键词
COVID-19; SARS-CoV-2; Vaccines; vaccines; NCOV-19; AZD1222; VACCINE; EFFICACY; BNT162B2; SCOTLAND; RISK;
D O I
10.1016/j.prrv.2021.07.001
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARSCoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [41] Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?
    Ghosh, Soumya
    Bornman, Charne
    Zafer, Mai M.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (05) : 555 - 560
  • [42] Ebola virus vaccines: Where do we stand?
    Pavot, Vincent
    CLINICAL IMMUNOLOGY, 2016, 173 : 44 - 49
  • [43] VACCINES AGAINST SCHISTOSOMIASIS - WHERE DO WE STAND
    BUTTERWORTH, AE
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1992, 86 (01) : 1 - 2
  • [44] Effects of SARS CoV-2, COVID-19, and its vaccines on male sexual health and reproduction: where do we stand?
    Lo, Sharon P.
    Hsieh, Tung-Chin
    Pastuszak, Alexander W.
    Hotaling, James M.
    Patel, Darshan P.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2022, 34 (02) : 138 - 144
  • [45] Effects of SARS CoV-2, COVID-19, and its vaccines on male sexual health and reproduction: where do we stand?
    Sharon P. Lo
    Tung-Chin Hsieh
    Alexander W. Pastuszak
    James M. Hotaling
    Darshan P. Patel
    International Journal of Impotence Research, 2022, 34 : 138 - 144
  • [46] B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
    Mehta, Puja
    Porter, Joanna C.
    Chambers, Rachel C.
    Isenberg, David A.
    Reddy, Venkat
    LANCET RHEUMATOLOGY, 2020, 2 (10): : E589 - E590
  • [47] Noninvasive respiratory support and invasive ventilation in COVID-19 Where do we stand today?
    Schroeder, Ines
    Irlbeck, Michael
    Zoller, Michael
    ANAESTHESIST, 2022, 71 (05): : 333 - 339
  • [48] Hematology Oncology Patients' Care in a Pandemic Situation of COVID-19: Where Do We Stand?
    Ali, Kashif
    Wajdi, Mehwish
    Al-Quteimat, Osama
    HOSPITAL PHARMACY, 2021, 56 (06) : 622 - 623
  • [49] Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?
    Falchetti, A.
    Mohseni, M.
    Tramontana, F.
    Napoli, N.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (11) : 2521 - 2524
  • [50] Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?
    A. Falchetti
    M. Mohseni
    F. Tramontana
    N. Napoli
    Journal of Endocrinological Investigation, 2021, 44 : 2521 - 2524